China Pharma Holdings Inc (CPHI) — Strategic Asset Allocation Index
China Pharma Holdings Inc (CPHI) has a Strategic Asset Allocation Index of 370.1% as of September 2022. Strategic assets (PP&E of $10.49 Million plus long-term investments of $-) total $10.49 Million, measured against net assets of $2.83 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check CPHI cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
China Pharma Holdings Inc Strategic Asset Allocation Index (2007–2021)
This chart shows how China Pharma Holdings Inc's Strategic Asset Allocation Index has evolved across 15 annual periods from 2007 to 2021. As of September 2022, the index stands at 370.1%, representing strategic assets of $10.49 Million against net assets of $2.83 Million USD. See how financially flexible is China Pharma Holdings Inc to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for China Pharma Holdings Inc (2007–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for China Pharma Holdings Inc from 2007 to 2021, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see China Pharma Holdings Inc (CPHI) market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 222.8% | $13.41 Million | $13.41 Million | $- | $6.02 Million | ▲ +27.7 pp |
| 2020 | 195.1% | $15.61 Million | $15.61 Million | $- | $8.00 Million | ▲ +18.5 pp |
| 2019 | 176.6% | $16.31 Million | $16.31 Million | $- | $9.24 Million | ▲ +112.7 pp |
| 2018 | 63.9% | $19.29 Million | $19.29 Million | $0.00 | $30.20 Million | ▲ +9.2 pp |
| 2017 | 54.7% | $23.54 Million | $23.54 Million | $0.00 | $43.07 Million | ▲ +12.3 pp |
| 2016 | 42.4% | $24.97 Million | $24.97 Million | $0.00 | $58.91 Million | ▲ +1.9 pp |
| 2015 | 40.5% | $29.39 Million | $29.39 Million | $0.00 | $72.64 Million | ▲ +8.6 pp |
| 2014 | 31.9% | $33.88 Million | $33.88 Million | $- | $106.25 Million | ▲ +9.1 pp |
| 2013 | 22.7% | $30.24 Million | $30.24 Million | $- | $132.94 Million | ▲ +16.7 pp |
| 2012 | 6.1% | $9.03 Million | $9.03 Million | $- | $148.52 Million | ▲ +1.6 pp |
| 2011 | 4.4% | $6.33 Million | $6.33 Million | $- | $142.48 Million | ▼ -1.0 pp |
| 2010 | 5.4% | $6.37 Million | $6.37 Million | $- | $117.94 Million | ▼ -2.0 pp |
| 2009 | 7.4% | $6.71 Million | $6.71 Million | $- | $90.40 Million | ▼ -2.2 pp |
| 2008 | 9.6% | $6.74 Million | $6.74 Million | $- | $69.87 Million | ▲ +3.0 pp |
| 2007 | 6.6% | $2.62 Million | $2.62 Million | $- | $39.76 Million | — |